Stifel analyst Jonathan Block said the firm's Q2 Animal Health survey highlighted how well-positioned Zoetis' product pipeline is, leading him to expect upside to his "Street high" 2019-2022 revenue and EPS estimates. In the survey, "the Triple," feline pain, canine pain and feline atopic dermatitis accounted for "the vast majority" of pharmaceutical product innovations that Veterinarians want, all of which Zoetis could or should bring to market over the next 1-2+ years, said Block. He keeps a Buy rating and $140 price target on Zoetis shares, which he views as a "core multi-year holding."